Corcept Therapeutics (CORT) Net Cash Flow (2010 - 2026)

Corcept Therapeutics has disclosed Net Cash Flow across 17 years of filings, most recently posting -$11.5 million for Q1 2026.

• Net Cash Flow for Q1 2026 came in at -$11.5 million, up 69.98% year-over-year; the trailing twelve-month figure through Mar 2026 was $18.1 million (up 130.17% YoY), and the FY2025 annual result was -$8.6 million, down 12.46% from the prior year.
• Net Cash Flow came in at -$11.5 million for Q1 2026 at Corcept Therapeutics, down from -$4.6 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $233.6 million in Q1 2023 to a low of -$127.6 million in Q2 2023.
• The 5-year median for Net Cash Flow is -$4.6 million (2025), against an average of $1.8 million.
• Across the five-year window, Net Cash Flow jumped 2107.68% in 2022 and sank 506.64% in 2023, its largest moves.
• Corcept Therapeutics' Net Cash Flow stood at $16.1 million in 2022, then jumped by 45.42% to $23.4 million in 2023, then slumped by 137.9% to -$8.9 million in 2024, then jumped by 47.99% to -$4.6 million in 2025, then plunged by 148.75% to -$11.5 million in 2026.
• The last three Net Cash Flow figures came in at -$11.5 million (Q1 2026), -$4.6 million (Q4 2025), and $22.7 million (Q3 2025), per Business Quant data.